Biotechs turn to gene silencing for obesity drugs that can last longer than Wegovy; FDA poised to publish guidelines for clinical trial diversity

Taking stock of the drug industry, from the lab to the medicine chest

May 23, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Marian F. Moratinos for STAT STAT+ | Biotechs turn to gene silencing for obesity drugs that can last longer than Wegovy As shown in STAT's Obesity Drug Tracker, Regeneron and others are using RNA interference to target genetics, rather than hormones like GLP-1. By Allison DeAngelis and Elaine Chen STAT+ | FDA poised to publish guidelines for clinical trial diversity Congress recently passed a law requiring companies to give the FDA their plans for diversifying clinical trials. By John Wilkerson STAT+ | Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again, and other thoughts Plus, some other thoughts on the company's decision to sell Royalty Pharma a share of its heart drug for up to $575 million. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser